<DOC>
	<DOCNO>NCT02346877</DOCNO>
	<brief_summary>This study evaluate whether effect personalize patient counsel tool , Information-Motivation-Strategy ( IMS ) base result Beliefs Medicines Questionnaire ( BMQ ) improve persistence Enbrel ( etanercept ) therapy week 52 subject rheumatoid arthritis historical control estimate standard care .</brief_summary>
	<brief_title>Evaluate Effects Personalized Patient Counselling Enbrel速 Therapy Adults With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Subject provide informed consent prior study specific procedure diagnose rheumatoid arthritis eligible treatment Enbrel速 ( etanercept ) Subject prescribed access commercial Enbrel速 ( etanercept ) ( 50mg weekly ) accord subject 's health insurance Completion require safety assessment start treatment Enbrel速 ( etanercept ) Other Inclusion Criteria May apply . previously receive treatment biologic disease modify antirheumatic drug ( DMARD ) and/or Tofacitinib . Malignancy ( except nonmelanoma skin cancer , cervical breast ductal carcinoma situ ) within last 5 year refusal consent enroll Enliven program Currently receive treatment another investigational device drug study , less 30 day since end treatment another investigational device drug study ( ) Other Exclusion Criteria May Apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Enbrel</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
</DOC>